CAP-CMV GmbH Raises New Funds to Further Develop its Novel hCMV Vaccine and Appoints New CEO
CAP-CMV GmbH, a company focusing exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (hCMV) infection and a spin-out of CEVEC Pharmaceuticals GmbH, has announced that it raised in total €1.7 million from its investors Peppermint Venture Partners (PVP), NRW.Bank, Creathor Venture, KfW and private investors in a combined seed/start-up investment.
The funds will be used to advance further it´s vaccine candidate, HCMV dense bodies (DBs) derived from CEVEC´s human CAP cell technology. DBs contain highest amount of relevant antigens, and were shown to elicit strong and lasting humoral and cellular immune responses in preclinical models. DBs are the ideal vaccine candidate to prevent hCMV caused diseases. Congenital infection with hCMV is a leading cause for neonatal disabilities. As up to 40% of the population carry this virus the hCMV infection is also a major health threat to recipients of solid organ or stem transplantations.
Wolfgang Kintzel, start-up CEO of CAP-CMV comments: “We are very happy that we could now secure our Series A financing round for this unique vaccine project. The money will be used to prove in various animal studies the clear advantages of our system against other technologies as well as advancing our pre-clinical programmes.”
Also in March CAP-CMV´s shareholders appointed Albrecht Läufer as its new CEO. Joachim Rautter, Managing Partner at PVP, and speaker of CAP-CMV´s advisory board says: “Wolfgang has put CAP-CMV on the right track and we thank him for his tremendous efforts to establish the company. We now welcome Albrecht and wish him success in taking forward CAP-CMV on its growth path while Wolfgang will be appointed to the board of CAP-CMV”. Albrecht Läufer was cofounder and first CEO of Vakzine Projekt Management GmbH (VPM), the company which has started preclinical development of HCMV dense bodies and then licensed the project to CAP-CMV.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance